PMID- 19762531
OWN - NLM
STAT- MEDLINE
DCOM- 20091001
LR  - 20220317
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 132
IP  - 4
DP  - 2009 Oct
TI  - Emerging technologies for assessing HER2 amplification.
PG  - 539-48
LID - 10.1309/AJCPV2I0HGPMGBSQ [doi]
AB  - Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are 
      eligible for trastuzumab treatment; therefore, accurate assessment of HER2 status 
      is essential. Until recently, only 2 methods were validated for determining the 
      HER2 status of breast tumors in the routine diagnostic setting: 
      immunohistochemical analysis and fluorescence in situ hybridization (FISH). 
      Recently, bright-field in situ hybridization techniques such as chromogenic in 
      situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH), which 
      combine features of immunohistochemical analysis and FISH, have been introduced 
      for the determination of HER2 status. These new techniques use a peroxidase 
      enzyme-labeled probe with chromogenic detection, instead of a fluorescent-labeled 
      probe, allowing results to be visualized by standard bright-field microscopy. 
      Thus, the histologic features and HER2 status of a specimen can be evaluated in 
      parallel. Moreover, signals do not decay over time. This review discusses recent 
      publications regarding CISH and SISH testing, including results scoring and 
      concordance between FISH and immunohistochemical analysis.
FAU - Penault-Llorca, Frederique
AU  - Penault-Llorca F
AD  - Department de Pathologie, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex, 
      France.
FAU - Bilous, Michael
AU  - Bilous M
FAU - Dowsett, Mitch
AU  - Dowsett M
FAU - Hanna, Wedad
AU  - Hanna W
FAU - Osamura, Robert Yoshiyuki
AU  - Osamura RY
FAU - Ruschoff, Josef
AU  - Ruschoff J
FAU - van de Vijver, Marc
AU  - van de Vijver M
LA  - eng
GR  - BREAST CANCER NOW RESEARCH CENTRE/BCN_/Breast Cancer Now/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Chromogenic Compounds)
RN  - 3M4G523W1G (Silver)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Algorithms
MH  - Antibodies, Monoclonal
MH  - Antibodies, Monoclonal, Humanized
MH  - Breast Neoplasms/genetics
MH  - Chromogenic Compounds
MH  - *Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Observer Variation
MH  - Receptor, ErbB-2/biosynthesis/genetics
MH  - Silver
MH  - Trastuzumab
RF  - 72
EDAT- 2009/09/19 06:00
MHDA- 2009/10/02 06:00
CRDT- 2009/09/19 06:00
PHST- 2009/09/19 06:00 [entrez]
PHST- 2009/09/19 06:00 [pubmed]
PHST- 2009/10/02 06:00 [medline]
AID - 132/4/539 [pii]
AID - 10.1309/AJCPV2I0HGPMGBSQ [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ.